Myriad Genetics Inc (MYGN)

10:10 AM

Hologic vs. MYGN: Which Molecular Diagnostics Player Has More Upside? - TradingView

10:10 AM

01:33 AM

Cancer Biopsy Market Detailed In New Research Report 2025 | - openPR.com

01:33 AM

Apr 21, 2025

Press Release Distribution & PR Platform - ACCESS Newswire

Apr 21, 2025

Apr 21, 2025

Myriad Genetics (MYGN) Study Shows Reduced Hospitalizations with GeneSight Test | MYGN Stock News - GuruFocus

Apr 21, 2025

Apr 21, 2025

Myriad Genetics Study Finds GeneSight Test Reduces Psychiatric Hospitalizations in Major Depressive Disorder Patients - Nasdaq

Apr 21, 2025

Apr 21, 2025

Myriad Genetics Announces Study Results Show Patients with Depression had Fewer Psychiatric Hospitalizations after GeneSight Testing | MYGN Stock News - GuruFocus

Apr 21, 2025

Apr 21, 2025

Myriad Genetics Announces Study Results Show Patients with - GlobeNewswire

Apr 21, 2025

Apr 21, 2025

New Study: Depression Patients See 40% Drop in Drug Complications with GeneSight Genetic Test - Stock Titan

Apr 21, 2025

Apr 17, 2025

Demystifying Myriad Genetics: Insights From 10 Analyst Reviews - Benzinga

Apr 17, 2025

Apr 16, 2025

Pancreatic Cancer Market Growth, Trends & Forecast 2024-2031 | - openPR.com

Apr 16, 2025

Apr 15, 2025

Myriad Genetics price target lowered to $9 from $11 at BofA - Yahoo Finance

Apr 15, 2025

Apr 15, 2025

Myriad Genetics (MYGN) Sees Price Target Lowered by BofA Amid Po - GuruFocus

Apr 15, 2025

Apr 11, 2025

8-DAY DEADLINE ALERT” HAGENS BERMAN, NATIONAL TRIAL ATTORNEYS, Encourages Myriad Genetics (MYGN) Investors Who Suffered Significant Losses to Contact Its Attorneys, Application Deadline is Approaching - ACCESS Newswire

Apr 11, 2025

Apr 11, 2025

Genetic Screening Testing for Preventive Health Market Top - openPR.com

Apr 11, 2025

Apr 10, 2025

Myriad Genetics price target lowered to $19 from $27 at Raymond James - MSN

Apr 10, 2025

Apr 09, 2025

Guggenheim Downgrades Myriad Genetics to Neutral From Buy - marketscreener.com

Apr 09, 2025

Apr 08, 2025

Myriad Genetics Announces Inducement Awards | MYGN Stock News - GuruFocus

Apr 08, 2025

Apr 08, 2025

Myriad Genetics Announces Inducement Awards - GlobeNewswire

Apr 08, 2025

Apr 08, 2025

Minimal Residual Disease Testing Market Forecast Report, 2025-2030 - GlobeNewswire Inc.

Apr 08, 2025

Apr 07, 2025

Myriad Genetics appoints new CCO to drive growth By Investing.com - Investing.com South Africa

Apr 07, 2025

Apr 07, 2025

Myriad Genetics appoints new CCO to drive growth - Investing.com Australia

Apr 07, 2025

Apr 07, 2025

Myriad Genetics Names Brian Donnelly As New Chief Commercial Officer - MarketScreener

Apr 07, 2025

Apr 07, 2025

Myriad Genetics Names Brian Donnelly as New Chief Commercial Officer - GlobeNewswire

Apr 07, 2025

Apr 07, 2025

Healthcare Tech Leader From Amazon and Illumina Takes Commercial Helm at Myriad Genetics - Stock Titan

Apr 07, 2025

Apr 03, 2025

Myriad Genetics stock hits 52-week low at $8.44 amid market challenges By Investing.com - Investing.com South Africa

Apr 03, 2025

Apr 03, 2025

Myriad Genetics stock hits 52-week low at $8.44 amid market challenges - Investing.com

Apr 03, 2025

Apr 02, 2025

Myriad Genetics, Inc. Investigated by Shareholder Rights Advocates – Investors Should Contact Levi & Korsinsky Regarding Potential Securities Law ViolationsMYGN - ACCESS Newswire

Apr 02, 2025

Apr 01, 2025

10 Analysts Assess Myriad Genetics: What You Need To Know - Benzinga

Apr 01, 2025

Apr 01, 2025

(MYGN) Technical Data - news.stocktradersdaily.com

Apr 01, 2025

Apr 01, 2025

Scotiabank cuts Myriad Genetics target to $20, keeps outperform rating By Investing.com - Investing.com Canada

Apr 01, 2025

Mar 31, 2025

Cancer Biomarkers Market Set to Witness Significant Growth - openPR.com

Mar 31, 2025

Mar 28, 2025

Is Myriad Genetics Stock Worth Holding in Your Portfolio Now? - MSN

Mar 28, 2025

Mar 26, 2025

Myriad Genetics stock hits 52-week low at $9.36 amid challenges By Investing.com - Investing.com South Africa

Mar 26, 2025

Mar 26, 2025

Myriad Genetics stock hits 52-week low at $9.36 amid challenges - Investing.com Australia

Mar 26, 2025

Mar 26, 2025

Myriad (MYGN) Down 17.1% Since Last Earnings Report: Can It Rebound? - Yahoo Finance

Mar 26, 2025

Mar 25, 2025

Press Release Service: United States Molecular Diagnostics Market Forecast Report and Company Analysis 2025-2033 Featuring F Hoffmann-la Roche, Illumina, Hologic, Agilent, Qiagen, Myriad Genetics, Abbott, Danaher, BD & CoResearchAndMarkets.co - CRISPR Medicine News

Mar 25, 2025

Mar 22, 2025

Trend Tracker for (MYGN) - Stock Traders Daily

Mar 22, 2025

Mar 20, 2025

Global Preventive Healthcare Technologies And Services Market - openPR

Mar 20, 2025

Mar 17, 2025

The Future of Genetic Testing: Industry Growth, Trends & Key - openPR

Mar 17, 2025

Mar 17, 2025

Myriad Genetics (MYGN): Buy, Sell, or Hold Post Q4 Earnings? - Yahoo Finance

Mar 17, 2025

Mar 16, 2025

Myriad Genetics, Inc. (NASDAQ:MYGN) Not Doing Enough For Some Investors As Its Shares Slump 31% - Simply Wall St

Mar 16, 2025

Mar 15, 2025

Myriad Genetics upgraded at Piper Sandler on balanced risk reward setup - MSN

Mar 15, 2025

Mar 12, 2025

Analyst Sees Bottom For Myriad Genetics Stock, Issues Upgrade - Benzinga

Mar 12, 2025

Mar 12, 2025

Myriad Genetics (MYGN) Stock Jumps on Analyst Upgrade - GuruFocus.com

Mar 12, 2025

Mar 12, 2025

Myriad Genetics Shares Rise After Upgrade From Piper Sandler -March 12, 2025 at 02:53 pm EDT - Marketscreener.com

Mar 12, 2025

Mar 12, 2025

Myriad Genetics stock upgraded at Piper Sandler (MYGN:NASDAQ) - Seeking Alpha

Mar 12, 2025

Mar 12, 2025

Why Are Myriad Genetics (MYGN) Shares Soaring Today - Yahoo Finance

Mar 12, 2025

Mar 12, 2025

This HubSpot Analyst Turns Bullish; Here Are Top 5 Upgrades For Wednesday - Benzinga

Mar 12, 2025